Literature DB >> 11177336

Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences.

U Rauch1, J I Osende, V Fuster, J J Badimon, Z Fayad, J H Chesebro.   

Abstract

PURPOSE: To describe the characteristics of thrombus formation on atherosclerotic plaques, the clinical expression of atherothrombosis in vascular disease, and some of the most recent therapeutic approaches in cardiovascular disease. DATA SOURCES: MEDLINE search for English-language articles on thrombosis and atherosclerosis published up to January 2000. Abstracts of recent international meetings on new aspects of thrombus formation and new therapeutic options were reviewed, and references from identified articles were selected and reviewed. STUDY SELECTION: Experimental, basic, clinical, and epidemiologic studies related to the pathophysiology of thrombosis on atherosclerotic lesions. Therapeutic approaches were obtained from experimental studies and large clinical investigations. DATA EXTRACTION: Arterial vessel wall substrate, rheologic conditions, and blood thrombogenicity influence the process of thrombus formation in arteries. Thrombus formation on disrupted atherosclerotic plaques or arterial erosions frequently causes acute coronary syndromes. Severe atherosclerosis of the aorta has been identified as an important morphologic indicator of an increased risk for thromboembolism. Current antithrombotic therapies available as long-term treatment for patients with cardiovascular disease are often not effective enough to prevent acute thrombotic events and deterioration of atherosclerosis. DATA SYNTHESIS: Improved understanding of the pathophysiology of thrombus formation on atherosclerotic plaques has led to the development of new therapeutic approaches. Glycoprotein IIb/IIIa, tissue factor, factor Xa, and thrombin inhibitors as well as combined antithrombotic therapy, such as aspirin plus a thienopyridine plus warfarin, are being evaluated as new possible options for the treatment of arterial thrombosis.
CONCLUSIONS: Long-term treatment with potent antithrombotic drugs, such as tissue factor or factor Xa inhibitors, that effectively block thrombosis without causing bleeding complications could help reduce death from cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11177336     DOI: 10.7326/0003-4819-134-3-200102060-00014

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  44 in total

Review 1.  Transient ischaemic attacks : new approaches to management.

Authors:  Ramesh Madhavan; Seemant Chaturvedi
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.

Authors:  Ulf Bertram; Martin Moser; Karlheinz Peter; Helmut F Kuecherer; Raffi Bekeredjian; Andreas Straub; Thomas K Nordt; Christoph Bode; Johannes Ruef
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

3.  Crystallization and preliminary crystallographic characterization of three peptidic inhibitors in complex with α-thrombin.

Authors:  Ana Carvalho Figueiredo; Cristina C Clement; Manfred Philipp; Pedro José Barbosa Pereira
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-12-21

4.  High mortality associated with intracardiac and intrapulmonary thromboses after cardiopulmonary bypass.

Authors:  Satoru Ogawa; James E Richardson; Tetsuro Sakai; Masahiro Ide; Kenichi A Tanaka
Journal:  J Anesth       Date:  2011-10-19       Impact factor: 2.078

5.  Human platelet alloantigens HPA-1, HPA-2, and HPA-3 polymorphisms associated with extent of severe coronary artery disease.

Authors:  Nesrine Abboud; Lakdhar Ghazouani; Sonia Ben-Hadj-Khalifa; Fatma Anabi; Faouzi Added; Ali Khalfallah; Brahim Nsiri; Wassim Y Almawi; Touhami Mahjoub
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

6.  52-year-old woman with intractable nausea and vomiting.

Authors:  Jonathan H Smith; Nisha L Jacobs; Robert D Ficalora
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

7.  Anti-thrombotic activity of phenolic acids obtained from Salvia miltiorrhiza f. alba in TNF-α-stimulated endothelial cells via the NF-κB/JNK/p38 MAPK signaling pathway.

Authors:  Xianjing Zheng; Haimei Liu; Maoqiang Ma; Jianbo Ji; Faliang Zhu; Longru Sun
Journal:  Arch Pharm Res       Date:  2021-04-13       Impact factor: 4.946

Review 8.  Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis.

Authors:  Roberto Corti; Randolph Hutter; Juan Jose Badimon; Valentin Fuster
Journal:  J Thromb Thrombolysis       Date:  2004-02       Impact factor: 2.300

9.  Catheter based intracoronary brachytherapy leads to increased platelet activation.

Authors:  M Jaster; V Fuster; P Rosenthal; M Pauschinger; Q-V Tran; D Janssen; W Hinkelbein; P Schwimmbeck; H-P Schultheiss; U Rauch
Journal:  Heart       Date:  2004-02       Impact factor: 5.994

10.  Relationship between platelet activation related factors and polymorphism of related genes in patients with coronary heart disease of blood-stasis syndrome.

Authors:  Mei XUE; Ke-ji CHEN; Hui-jun YIN
Journal:  Chin J Integr Med       Date:  2008-12-12       Impact factor: 1.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.